Brief: Enzychem Lifesciences Files IND Application To FDA For Phase 2 Study Of Ec-18 In Preventing ARDS Due To Covid-19 Pneumonia
13/07/2020 13:35
July 13 (Reuters) - Enzychem Lifesciences Corp 183490.KQ :
* ENZYCHEM LIFESCIENCES FILES IND APPLICATION TO FDA FOR
PHASE 2
STUDY OF EC-18 IN PREVENTING ACUTE RESPIRATORY DISTRESS SYNDROME
(ARDS) DUE TO COVID-19 PNEUMONIA
* ENZYCHEM LIFESCIENCES CORP - PHASE 2 STUDY FOR EC-18 IN
PREVENTING ARDS DUE TO NOVEL CORONAVIRUS PNEUMONIA IS CURRENTLY
ONGOING IN SOUTH KOREA
Source text for Eikon: ID:nPn8BcCsDa
Further company coverage: 183490.KQ
(Reuters.Briefs@thomsonreuters.com)
Recent news on Enzychem Lifesciences
See all newsBrief: Enzychem Lifesciences To Divest 8 Billion Won Worth Of Own Shares
Brief: Enzychem Lifesciences Announces Completion Of Clinical Study Report (Csr) For Phase 2 Study Of Ec-18 In Chemoradiation-Induced Oral Mucositis
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot (updated)
Brief: Cadila Healthcare Inks Deal With South Korea's Enzychem For Plasmid DNA Vaccine
South Korea's Enzychem to make Indian drugmaker Cadila's COVID-19 shot